- LLY Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
8-K Filing
Eli Lilly and (LLY) 8-KFinancial statements and exhibits
Filed: 18 Mar 02, 12:00am
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 13, 2002
ELI LILLY AND COMPANY
(Exact name of registrant as specified in its charter)
Indiana (State or Other Jurisdiction of Incorporation) | 001-06351 (Commission File Number) | 35-040950 (I.R.S. Employer Identification No.) | ||
Lilly Corporate Center Indianapolis, Indiana (Address of Principal Executive Offices) | 46285 (Zip Code) |
Registrant’s telephone number, including area code: (317) 276-2000
No Change
Form of Underwriting Agreement | ||||||||
Form of 6 Percent Note Due 2012 |
Item 7. Financial Statements and Exhibits.
Exhibit Number | Exhibit | |
(1) | Form of Underwriting Agreement, dated as of March 13, 2002, among Eli Lilly and Company and Goldman, Sachs & Co., J.P. Morgan Securities Inc., Deutsche Banc Alex. Brown Inc., Merrill Lynch Pierce, Fenner & Smith, Salomon Smith Barney Inc. and UBS Warburg LLC, relating to the issuance and sale by Eli Lilly and Company of $500,000,000 aggregate principal amount of its 6.00% Notes Due 2012. | |
(4) | Form of 6.00% Note Due 2012. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ELI LILLY AND COMPANY (Registrant) | ||
By: | /s/ Thomas W. Grein Name: Thomas W. Grein Title: Vice President and Treasurer |
Dated: March 18, 2002
EXHIBIT INDEX
Exhibit Number | Exhibit | |
(1) | Form of Underwriting Agreement, dated as of March 13, 2002, among Eli Lilly and Company and Goldman, Sachs & Co., J.P. Morgan Securities Inc., Deutsche Banc Alex. Brown Inc., Merrill Lynch Pierce, Fenner & Smith, Salomon Smith Barney Inc. and UBS Warburg LLC, relating to the issuance and sale by Eli Lilly and Company of $500,000,000 aggregate principal amount of its 6.00% Notes Due 2012. | |
(4) | Form of 6.00% Note Due 2012. |